These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 17214110

  • 21. Factors influencing medical treatment of heart failure patients in Spanish internal medicine departments: a national survey.
    Román-Sánchez P, Conthe P, García-Alegría J, Forteza-Rey J, Montero M, Montoto C.
    QJM; 2005 Feb; 98(2):127-38. PubMed ID: 15655095
    [Abstract] [Full Text] [Related]

  • 22. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX, Ye X, Lee KY, Dupclay L, Plauschinat C.
    Clin Ther; 2008 Feb; 30 Pt 2():2217-27. PubMed ID: 19281916
    [Abstract] [Full Text] [Related]

  • 23. Association of blood pressure and its evolving changes with the survival of patients with heart failure.
    Grigorian-Shamagian L, Gonzalez-JuAnatey JR, Vazquez R, Cinca J, Bayes-Genis A, Pascual D, Fernandez-Palomeque C, Bardaji A, Almendral J, Nieto V, Macaya C, Jimenez RP, de Luna AB, Muerte Subita En La Insuficiencia Cardiaca (MUSIC) Group.
    J Card Fail; 2008 Sep; 14(7):561-8. PubMed ID: 18722321
    [Abstract] [Full Text] [Related]

  • 24. Heart failure due to left ventricular systolic dysfunction: treatment at discharge from hospital and at one year.
    Houpe D, Peltier M, Cohen-Solal A, Béguin M, Lévy F, Slama M, Chapelain K, Tribouilloy C.
    Int J Cardiol; 2005 Sep 01; 103(3):286-92. PubMed ID: 16098391
    [Abstract] [Full Text] [Related]

  • 25. [Medical treatment of heart failure: an analysis of actual treatment practices in outpatients in Switzerland. The Swiss "IMPROVEMENT of HF" Group].
    Muntwyler J, Follath F.
    Schweiz Med Wochenschr; 2000 Aug 26; 130(34):1192-8. PubMed ID: 11013922
    [Abstract] [Full Text] [Related]

  • 26. Temporal improvement in heart failure survival related to the use of a nurse-directed clinic and recommended pharmacological treatment.
    Andersson B, Kjörk E, Brunlöf G.
    Int J Cardiol; 2005 Oct 10; 104(3):257-63. PubMed ID: 16186053
    [Abstract] [Full Text] [Related]

  • 27. Differences between cardiologists and internists in the management of heart failure. Medical guidelines compared with every-day practice.
    Stawicki S, Roik M, Jasik M, Kosior D, Scisło P, Kochanowski J, Dembe K, Steckiewicz R, Karnafel W, Opolski G.
    Kardiol Pol; 2004 Nov 10; 61(11):431-9; discussion 440-1. PubMed ID: 15883591
    [Abstract] [Full Text] [Related]

  • 28. Translating guidelines into clinical practice: benefits of an acute heart failure unit .
    Fonseca C, Ceia F, Sarmento PM, Marques F, Covas R, Aleixo A.
    Rev Port Cardiol; 2007 Nov 10; 26(11):1111-28. PubMed ID: 18297836
    [Abstract] [Full Text] [Related]

  • 29. Treatment practices in heart failure with preserved left ventricular ejection fraction: a prospective observational study.
    Peltier M, Houpe D, Cohen-Solal A, Béguin M, Levy F, Tribouilloy C.
    Int J Cardiol; 2007 Jun 12; 118(3):363-9. PubMed ID: 17049391
    [Abstract] [Full Text] [Related]

  • 30. Adherence to evidence-based guidelines for heart failure in physicians and their patients: lessons from the Heart Failure Adherence Retention Trial (HART).
    Calvin JE, Shanbhag S, Avery E, Kane J, Richardson D, Powell L.
    Congest Heart Fail; 2012 Jun 12; 18(2):73-8. PubMed ID: 22432552
    [Abstract] [Full Text] [Related]

  • 31. Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003.
    Lamb DA, Eurich DT, McAlister FA, Tsuyuki RT, Semchuk WM, Wilson TW, Blackburn DF.
    Circ Cardiovasc Qual Outcomes; 2009 May 12; 2(3):228-35. PubMed ID: 20031842
    [Abstract] [Full Text] [Related]

  • 32. Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the get with the guidelines quality-improvement program.
    Lewis WR, Ellrodt AG, Peterson E, Hernandez AF, LaBresh KA, Cannon CP, Pan W, Fonarow GC.
    Circ Cardiovasc Qual Outcomes; 2009 Nov 12; 2(6):633-41. PubMed ID: 20031902
    [Abstract] [Full Text] [Related]

  • 33. Assessment of drug treatment quality in two Danish health-care centres.
    Edfors K, Andersen SE.
    Dan Med Bull; 2011 Jan 12; 58(1):A4218. PubMed ID: 21205564
    [Abstract] [Full Text] [Related]

  • 34. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK, Duval S, Manske C, Vazquez G, Barber C, Miller L, Luepker RV.
    Am Heart J; 2007 Jun 12; 153(6):1064-73. PubMed ID: 17540211
    [Abstract] [Full Text] [Related]

  • 35. How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts.
    McAlister FA, Tu JV, Newman A, Lee DS, Kimber S, Cujec B, Armstrong PW.
    Eur Heart J; 2006 Feb 12; 27(3):323-9. PubMed ID: 16105850
    [Abstract] [Full Text] [Related]

  • 36. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.
    Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB, OPTIMIZE-HF Investigators and Hospitals.
    J Am Coll Cardiol; 2007 Aug 21; 50(8):768-77. PubMed ID: 17707182
    [Abstract] [Full Text] [Related]

  • 37. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.
    Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J.
    Am J Kidney Dis; 2005 Dec 21; 46(6):1080-7. PubMed ID: 16310574
    [Abstract] [Full Text] [Related]

  • 38. Spironolactone use in patients with heart failure.
    Trujillo JM, Gonyeau MJ, DiVall MV, Alexander SL.
    J Clin Pharm Ther; 2004 Apr 21; 29(2):165-70. PubMed ID: 15068406
    [Abstract] [Full Text] [Related]

  • 39. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM, Plokker HW, Lok DJ, Boomsma F, van der Horst FA, van Veldhuisen DJ, van Gilst WH, Voors AA.
    Int J Cardiol; 2006 Jan 26; 106(3):367-72. PubMed ID: 16337046
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, Yusuf S, Michelson EL, Swedberg K, Pfeffer MA, CHARM Investigators.
    Eur J Heart Fail; 2008 Feb 26; 10(2):157-63. PubMed ID: 18242128
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.